NSE: LAXMIDENTL · BSE: 544339 · ISIN INE0WO601020
Laxmi Dental Limited stock analysis
Laxmi Dental Limited ranks #2143 in the TickerSutra evidence-ranked universe with a score of 48/100 and 89% data confidence. The latest captured fundamentals show ROCE of 14.9%, quarterly sales growth of 13.9% and quarterly profit growth of 22.8%.Avoid / exit review
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.05×
- 19.7% three-year sales CAGR
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹137cr | ₹7cr | ₹-19cr | 4.8% |
| 2023 | ₹162cr | ₹9cr | ₹-4cr | 6.0% |
| 2024 | ₹194cr | ₹24cr | ₹25cr | 13.0% |
| 2025 | ₹239cr | ₹43cr | ₹32cr | 18.0% |
| 2026 | ₹278cr | ₹43cr | ₹29cr | 16.0% |
| TTM | ₹287cr | ₹46cr | ₹31cr | 16.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Laxmi Dental Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026
RoutineLaxmi Dental Ltd - 544339 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · 25 Sept 2026Proceeding of the 22nd Annual General Meeting of the Company held on Friday, September 25, 2026.
RoutineTrading WindowBSE · 25 Sept 2026Laxmi Dental Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineGeneral UpdatesNSE · 18 Sept 2026Laxmi Dental Limited has informed the Exchange about General Updates
RoutineLaxmi Dental Ltd - 544339 - Intimation Of Approval For Listing And Trading Of Further Issue Of Equity Shares Under Laxmi Dental Employee Stock Option Scheme 2024BSE · 18 Sept 2026National Stock Exchange of India Limited (''NSE'') and BSE Limited (''BSE'') have issued their respective approvals for listing of further issue of 7,911 Equity Shares of face value of ....
MANAGEMENT COMMENTARY
Signals from filed documents
As India's only fully integrated dental products company, we believe this ecosystem is one of our most significant competitive advantages. As we look ahead, we will continue investing in innovation, expanding digital adoption, strengthening our manufacturing capabilities and growing our presence across domestic as well as international markets. We are equally committed to nurturing the partnerships that have been ins
India’s Only Integrated Dental Products Company The Company brings together patient-specific laboratory offerings, clear aligners, aligner materials and equipment, intraoral scanners and paediatric dental products within a single platform. Its backward integration into key materials and manufacturing equipment is complemented by direct access to dental professionals through a dentist-led B2B2C model. This integrated
Going forward, we continue to execute our strategy centred around expanding our market reach, driving product innovation, accelerating digitalization, and building a trusted and well- recognized brand in the dental industry. With this, we remain confident in delivering sustainable and long-term profitable growth. I will now hand it over to our CFO, Mr.
Backed by patient-specific manufacturing, digital workflows and a network of over 22,000 clinics and dentists, its ecosystem enhances quality, efficiency and cross-selling opportunities while accelerating the adoption of digital dentistry. Key Highlights Second-largest player in the domestic laboratory business and the largest export laboratory, with increasing adoption of digital dentistry Vertically integrated and
• Evaluate opportunities for geographical diversification over time. Competitive Risk The Company operates in a competitive industry characterised by pricing pressure and the presence of multiple market participants. • Provide differentiated services and solutions.
Sumona Chakraborty, Non-Executive, Non-Independent Nominee Director with effect from closure of business hours on 06 June, 2025 the Nomination Remuneration Committee was reconstituted by appointing Ms. Anjana Grewal as Member of the Committee as approved by the Board in its meeting dated 28 July, 2025. ²After the end of the financial year and before signing of this report the Company has dissolved its Risk Management
The Scheme provides for merger of the business of Bizdent Devices Private Limited, subject to receipt of requisite statutory and regulatory approvals. As the Scheme is currently awaiting approval from the appropriate authorities, no effect of the proposed merger has been given in these standalone financial statements. As per our report of even date attached For M S K A & Associates LLP (Formerly known as M S K A & As
The website hosts a dedicated “Investors” section, inter alia, the financial results, presentations to investors and analysts, audio recordings and transcripts of earnings calls, corporate governance disclosures, disclosures under Regulation 46 of Listing Regulations and all other disclosures mandated under SEBI Listing Regulations are available. (c) Official news releases, institutional investors/ analyst meet: The
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…